Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
- Conditions
- Mesothelioma, Malignant
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 124
- Registration Number
- NCT02357147
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
- Conditions
- AdenocarcinomaColorectal CancerCarcinoma, Non-Small-Cell LungBreast CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 27
- Registration Number
- NCT01761240
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
- Conditions
- Anaplastic Large Cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaNoncutaneous Extranodal LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisChildhood Burkitt Lymphoma
- Interventions
- Biological: anti-endosialin/TEM1 monoclonal antibody MORAb-004Other: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 27
- Registration Number
- NCT01748721
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
- Conditions
- Metastatic Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 209
- Registration Number
- NCT01574716
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
- Conditions
- MesotheliomaOvarian CancerNon-small Cell Lung CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 6
- Registration Number
- NCT01521325
- Locations
- 🇺🇸
National Cacner Institue, Bethesda, Maryland, United States
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
- Conditions
- Colorectal CancerMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 154
- Registration Number
- NCT01507545
- Locations
- 🇺🇸
Providence St. Joseph Medical Center-Disney Family Cancer Center, Burbank, California, United States
🇺🇸St. Jude Heritage Healthcare, Fullerton, California, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 20
- Registration Number
- NCT01357759
- Locations
- 🇺🇸
Axis Clinical Trials, Los Angeles, California, United States
🇺🇸Seaview Jacksonville, LLC, Jacksonville, Florida, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
- Conditions
- Adenocarcinoma of the Lung
- Interventions
- Biological: FarletuzumabOther: Placebo
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 130
- Registration Number
- NCT01218516
- Locations
- 🇺🇸
Clinical Trials and Research Associates, Inc., Montebello, California, United States
🇺🇸Medical Specialists of the Palm Beaches, Deerfield Beach, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
- Conditions
- Advanced MelanomaMetastatic MelanomaMalignant Metastatic MelanomaMelanoma
- Interventions
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 18
- Registration Number
- NCT01212276
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
- Conditions
- Resectable, Non-functioning Pituitary Adenoma
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Morphotek
- Registration Number
- NCT01203618
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States